Company Description
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Laura Niklason |
Contact Details
Address: 2525 East North Carolina Highway 54 Durham, North Carolina 27713 United States | |
| Phone | 919 313 9633 |
| Website | humacyte.com |
Stock Details
| Ticker Symbol | HUMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1818382 |
| CUSIP Number | 44486Q103 |
| ISIN Number | US44486Q1031 |
| Employer ID | 85-1763759 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, Chief Executive Officer and Director |
| Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer and Treasurer |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
| Sabrina Osborne GPHR, SPHR | Chief People Officer |
| Lisa Molyneux | Chief Strategy Officer |
| Dr. Heather Connelly Ph.D. | Chief Quality and Regulatory Officer |
| Rick McElheny | Senior Vice President of Business Development |
| Jim Mercadante | Chief Commercial Officer |
| Dr. Todd E. Rasmussen M.D. | Chief Surgical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | SCHEDULE 13D/A | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 28, 2026 | SCHEDULE 13G/A | Filing |
| Jul 13, 2026 | SCHEDULE 13D/A | Filing |
| Jun 22, 2026 | SCHEDULE 13G | Filing |
| Jun 15, 2026 | SCHEDULE 13D/A | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 424B5 | Filing |